Therefore, it will be important for the end users of the new ACC/AHA performance measure set to incorporate this risk assessment process in order to achieve successful implementation as a key component of quality improvement for patients with HBP. Because the current NCQA and CMS performance measures for controlling HBP assess only the population with ACC/AHA stage 2 HBP,6 the writing committee 4 also felt that it was important to emphasize the 2017 Hypertension Clinical Practice Guidelines4 recommen- dations to lower BP below the 130/80-mmHg threshold for both ACC/AHA stage 2 and stage 1 patients. In for- mulating these new performance measures, the writing committee was sensitive to the fact that there is cur- rently not complete consensus among other guidelines from the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP)8 and also the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH).9 Nonetheless, despite this ongoing debate, the writing committee felt strongly that it is now time to move the US healthcare system ahead to reflect these differing points of view and expects that widespread use of this new measure set will help to achieve this goal. 